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Abstract 
Patents render prices of patented products unaffordable for general masses because of 
the 20 years monopoly granted to owner of the patent to manufacture, sell, and import 
the patented product. Overpricing caused by monopoly rights has serious human rights 
implications in case of pharmaceutical patents especially in situations of public health 
crisis. Compulsory licensing of patents has been provided under TRIPS Agreement as a 
legitimate safeguard to check abuse of monopoly and to deal with special situations of 
public health crisis. First part of this paper discusses relationship of TRIPS and the 
human right to health as TRIPS Agreement for the first time made it mandatory to 
protect all innovations including pharmaceuticals. Second part of this paper discusses 
rationale of compulsory licensing of pharmaceutical patents in the light of Indian case 
Bayer Corporation v. Natco Pharma Limited. Last part of this paper concludes the 
discussion.  
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1. Introduction 
 The concept of Intellectual Property Rights (hereinafter IPRs) is based on the principle 
that a person who comes with an original creation carrying a utility has an exclusive right to 
exploit their creation. IPRs protection is therefore a tool that can be used to foster innovation by 
providing temporary monopoly to the IPRs holders as a reward of their effort. As a result, 
consumers get improved goods and services. Competition law, on the other hand, is meant to 
ensure fair prices by preventing monopoly. The relationship between intellectual property rights 
and competition law is complex, and it has always been a challenge to strike a proper balance 
between competition and innovation protection.
1
 
Though common purpose of both IPRs and competition law is to enhance consumer 
welfare and promote innovation, the goals of intellectual property laws and competition law are 
often convergent. There is a conflict between the two because the former creates legal 
monopolies and the latter eliminates monopolies and anticompetitive practices.
2 
Patent
3
 protection, despite being contradictory to competition law, has been accepted 
across the globe because it provides incentive to innovate. Sometimes monopoly right provided 
to patent holder may be required to be breached in certain special situations when public interest 
                                                            
1 Compulsory Licensing And The Anti-Competitive Effects of Patents for Pharmaceutical Products: From A 
Developing Countries’ Perspective, 2,last accessed date February 13, 
2012,doi:http://www.idra.it/garnetpapers/C14A_Kaushik_A_Jaktar.pdf. 
2 Arutyunyan, Arutyun. “Proceedings of the Institute for European Studies”, International University Audentes, 
Tallinn University of Technology, Vol. 4 (2008),168 ,last accessed date February 13,2012, doi: 
http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=28&hid=122&sid=b06a26af-6028-4687-93e0-
06fa097c0197%40sessionmgr13. 
3 A grant of right to exclude others from making, using or selling one’s invention and includes right to license others 
to make, use or sell it. Black’s Law Dictionary 1125 (6th ed. 1990). 
A patent is a form of intellectual property. It consists of a set of exclusive rights granted by a sovereign state to an 
inventor or their assignee for a limited period of time in exchange for the public disclosure of an invention. 
demands so. For instance, in case of an outbreak of an epidemic, a pharmaceutical may be 
diluted compulsorily to the detriment of the patent owner. The philosophy underlying 
compulsory licensing is therefore based on an often repeated saying “Necessity is the mother of 
invention”.4 
2. Pharmaceutical Patent Protection versus Right to Health 
 The right to health as a human right has been recognized by a number of international 
instruments. In 1948, the United Nations Universal Declaration of Human Rights (hereinafter 
UDHR) stipulated that “Everyone has the right to a standard of living adequate for the health and 
well-being of himself and of his family, including food, clothing, housing, and medical care.”5 In 
1966, the right to health as a human right was reaffirmed under Article 12 of the International 
Covenant on Economic, Social and Cultural Rights (hereinafter ICESCR).
6
 The Convention on 
the Rights of Child,
7
 the International Convention on the Elimination of All Forms of Racial 
Discrimination (hereinafter ICERD), and the Convention on Elimination of all forms of 
Discrimination Against Women (hereinafter CEDAW)
8
 further elaborated right to health care.
9
 
                                                            
4 Tarun Jain, “Compulsory Licenses Under Trips and Its Obligations for Member Countries”, ICFAI Journal of 
Intellectual Property Rights, Vol. 8 Issue 1, (Feb2009),1,last accessed date February 13, 2012 
doi:http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=34&hid=122&sid=b06a26af-6028-4687-93e0-
06fa097c0197%40sessionmgr13.  
5 Article 25(1), Universal Declaration of Human Rights,  For details visit 
<http://www.un.org/en/documents/udhr/index.shtml#a25> (last accessed date April 22, 2012). 
6 The International Covenant on Economic, Social and Cultural Rights (ICESCR) is a multilateral treaty adopted by 
the United Nations General Assembly on 16 December 1966, and in force from 3 January 1976. 
Available at, < http://www2.ohchr.org/english/law/cescr.htm>, (last accessed date April 22, 2012). 
7 Article 24(1),  Convention on the Rights of Child 1989, Available at, < http://www.unicef.org/crc/> (last accessed 
date April 22, 2012) 
8 Article 12(1) and Article 14(2)(b), Convention on Elimination of all forms of Discrimination Against Women 
1979,online available at,< http://www.un.org/womenwatch/daw/cedaw/text/econvention.htm>, (last accessed date 
April 22, 2012). 
9 Article 5(e)(iv),  International Convention on the Elimination of All Forms of Racial Discrimination 
1965,available at 
doi:http://en.wikipedia.org/wiki/Convention_on_the_Elimination_of_All_Forms_of_Racial_Discrimination,(last 
accessed date April 22, 2012). 
Similarly, at national level, national constitutions of at least 135 states have recognized 
right to health as a human right.
10
 For instance, right to health care has been guaranteed
11
 in 
constitution of Brazil
12
, Thailand,
13
 and South Africa
14
. Access to essential medicines is a 
prerequisite to protect the fundamental human right to health.
15
 
States, owing to these commitments made at national and international level, are obliged 
to make arrangements for the protection of life and health of their nationals.
16
 States are therefore 
under an obligation not to interfere with the right to health care and to adopt all suitable and 
feasible administrative and legislative measures to make sure that this right is not violated. States 
should also prevent those trying to interfere with the right to health. Moreover, states, while 
entering into international agreements or treaties, should make sure that it would not have an 
adverse effect on the right to health. 
                                                            
10 Dilip K. DAS, “Intellectual Property Rights and the Doha Round”, Journal Of World Intellectual Property, 
(2005), 522, last accessed date February 13,2012, doi:http://onlinelibrary.wiley.com/doi/10.1111/j.1747-
1796.2005.tb00236.x/pdf. 
11 Pier DeRoo, “Public Non-Commercial Use Compulsory Licensing For Pharmaceutical Drugs In Government 
Health Care Programs”, Michigan Journal of International Law, (2011),364, last accessed date February 
13,2012,doi:http://students.law.umich.edu/mjil/uploads/articles/v32n2-deroo.pdf.  
12 Article 196,  Constitution of Brazil, available online, < http://karari.org/de/node/36870> , (last accessed date April 
22, 2012). 
13 Section 51, Constitution of the Kingdom of Thailand, ,last accessed date April 22, 
2012,doi:http://en.wikisource.org/wiki/Constitution_of_Thailand_%282007%29/Chapter_3. It provides the right to 
health care. 
14 Section 27, Constitution of South Africa. Available at,                                                                    
<www.info.gov.za/documents/constitution/1996/a108-96.pdf> , (last accessed date April 22, 2012). 
15 Jillian Clare Cohen-Kohler and Lisa Forman, “Addressing legal and political barriers to global pharmaceutical 
access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) and the imposition of TRIPS-plus standards, Health Economics”, Policy and Law, Vol.3,  
(2008),249,last accessed date February 13,2012, doi: 
http://journals.cambridge.org/action/displayFulltext?type=1&pdftype=1&fid=1914284&jid=HEP&volumeId=3&iss
ueId=03&aid=1914276. 
16 M. Rafiqul Islam, “The Generic Drug Deal of the WTO from Doha to Cancun, A Peripheral Response to a 
Perennial Conundrum”, Journal Of World Intellectual Property, Vol.7, Issue 5, (2005),689, >,last accessed date 
February 13,2012,http://onlinelibrary.wiley.com/doi/10.1111/j.1747-1796.2004.tb00224.x/pdf. 
Over 14 million patients of curable or preventable diseases die each year.
17
 The situation is even 
grimmer in the most affected regions of Asia and Africa.
18
 It may be astonishing to note that 
about 80 % of the total population of the world comprises of developing countries but they buy 
hardly 20 % of pharmaceuticals manufactured across the globe.
19
 Low purchasing power of the 
masses in these countries may be one of the major reasons behind this. Moreover, about 90 
percent people living in the third world pay for medicines from their own pocket.
20
 
Trade Related Aspects of Intellectual Property Rights (hereinafter TRIPS) Agreement 
introduced a strict legal regime for the protection of IPRs. Under TRIPS Agreement, WTO 
member countries are obliged to provide patent protection, for a period of 20 years to 
innovations in all fields of technology including pharmaceuticals.
21
 Prior to TRIPS, about fifty 
countries, including many of the present world’s developed countries, had excluded drugs from 
patent protection in their municipal laws. For instance, “Germany until 1968, Switzerland until 
1977, Italy until 1978, Norway, Portugal and Spain until 1992, Finland until 1995”.22   
                                                            
17 Third World Network, “TRIPS, Drugs and Public Health: Issues and Proposals”, Intellectual Property Rights 
Series, Vol.2, (2001),4,accessed date February 13,2012, http://www.twnside.org.sg/title2/IPR/pdf/ipr02.pdf.. 
18 Philippe Cullet, “Patents and medicines: the relationship between TRIPS and the human right to health”, 
International Affairs 79, (2003),143,last accessed date February 13,2012,  
doi:http://onlinelibrary.wiley.com/doi/10.1111/1468-2346.00299/pdf. 
19 Faizel Ismail, “The Doha Declaration on TRIPS and Public Health and the Negotiations in the WTO on Paragraph 
6why P h w Needs to join the Consensus”,  Journal of World Intellectual Property, Vol.6, Issue 3, (2003),395,last 
accessed date February 23,2012, doi: http://onlinelibrary.wiley.com/doi/10.1111/j.1747-1796.2003.tb00221.x/pdf. 
20 Rudolf V. Van Puymbroeck, “Basic Survival Needs and Access to Medicines – Coming to Grips with TRIPS: 
Conversion +Calculation”, Journal of Law, Medicine & Ethics, Vol.38, Issue3, (2010), 522,last accessed date 
February 13,2012,doi: http://onlinelibrary.wiley.com/doi/10.1111/j.1748-720X.2010.00510.x/pdf.  
21 Sandra Bartelt, “Compulsory Licences Pursuant to TRIPS Article 31 in the Light of the Doha Declaration on the 
TRIPS Agreement and Public Health”, Journal Of World Intellectual Property, Vol.6, Issue 2, (2003), 283,last 
accessed date February 23,2012,doi:http://onlinelibrary.wiley.com/doi/10.1111/j.1747-1796.2003.tb00202.x/pdf. 
22 F M Scherer: Jayashree Watal,  “Post-Trips Options for Access to Patented Medicines in Developing Countries”, 
Commission on Macroeconomics and Health, (2001), 4,last accessed date  March 23,2012, doi: 
http://www.icrier.org/pdf/jayawatal%20.pdf.  
The fact that patented drugs are unaffordable for general masses in the third world, 
because of monopoly provided to patent holders, raises serious concerns for developing countries 
considering stronger IPRs protection.
23
 While framing TRIPS Agreement human rights 
implications were not given due consideration. In 1990s outbreak of pandemics like HIV/AIDS
24
 
drew attention of the world community towards consequences of stringent pharmaceutical patent, 
protection provided under TRIPS Agreement, for patients in the poor countries. For the first 
time, public health concern emerged as a political issue at international level
25
 and it sparked 
serious debate at World Health Organization (WHO) and World Intellectual Property 
Organization (WIPO).
 26
    
The United Nations Sub-Commission on Human Rights, in 2001,
27
 recognized that “there 
are apparent conflicts between the intellectual property rights regime embodied in the TRIPS 
Agreement, on the one hand, and international human rights law, on the other.”28 WTO 
Ministerial Conference was held in 2001 at Doha; in this conference representatives of third 
world countries raised their voices and Doha Declaration 2001 and WTO General Council’s 
Waiver Decision of 2003 were the result of their efforts. Right of WTO member countries to 
                                                            
23 Richard P. Rozek, “The Effects of Compulsory Licensing on Innovation and Access to Health Care”, Journal of 
World Intellectual Property,  Vol.3, Issue 6, (2000),892, last accessed date  March 
23,2012,doi:http://onlinelibrary.wiley.com/doi/10.1111/j.1747-1796.2000.tb00158.x/pdf. 
24 A pandemic is an epidemic of infectious disease that spreads through human populations across a large region: for 
instance multiple continents, or even worldwide. For details visit <http://en.wikipedia.org/wiki/Pandemic>, (last 
accessed date April 23, 2012). 
25Robert Bird: Daniel R. Cahoy, “The Impact of Compulsory Licensing on Foreign Direct Investment: A Collective 
Bargaining Approach”, American Business Law Journal, Vol.45, Issue 2, (2008), 286, last accessed date  March 
23,2012,http://onlinelibrary.wiley.com/doi/10.1111/j.1744-1714.2008.00056.x/pdf. 
26 Jacques H.J. Bourgeois, “Thaddeus J. Burns, Implementing Paragraph 6 of the Doha Declaration on TRIP Sand 
Public Health The waiver Solution”, Vol.5, Issue 6,(2005), 836, last accessed date  March 
23,2012,doi:http://onlinelibrary.wiley.com/doi/10.1111/j.1747-1796.2002.tb00184.x/pdf. 
27 See Resolution 2001/21, Intellectual Property And Human Rights, United Nations Sub-Commission on 
Human Rights, UN Doc. E/CN.4/Sub.2/RES/2001/21 (2001),doi: 
http://www.unhchr.ch/huridocda/huridoca.nsf/%28Symbol%29/E.CN.4.SUB.2.RES.2001.21.En?Opendocument, 
(last accessed date April 24, 2012).  
28 DeRoo,” Public Non-Commercial Use”, 364.  
invoke safeguards, like compulsory licensing, provided under TRIPS Agreement was reaffirmed 
in the Doha Declaration 2001. Theoretically, safeguards have been provided in the TRIPS to deal 
with public health crisis but practically to what extent third world countries have availed these 
flexibilities is a debatable issue.
 29
 
The private and philanthropic sectors have been actively working for increasing 
availability of essential medicines in the most affected regions of the third world. The Bill and 
Melinda Gates Foundation
30
 AIDS program in Botswana is just one example. There are 
various instances where even the much criticized pharmaceutical companies have made non-
profit investments on humanitarian grounds. The first AIDS hospital and the first AIDS 
laboratory constructed by Bristol Myer-Squibb Philanthropy
31
 in Botswana (Africa), Pfizer’s32 
initiative to build the first Infectious Disease Institute in Uganda, the Institute for Tropical 
Diseases (NITD) built by Novartis
33
 in Singapore, and the AIDS Hospital built by Abbott 
Laboratories
34
 in Tanzania are some of the examples.
35
 
No doubt, these initiatives are providing access to health care to a limited number of 
people in some parts of the third world but only philanthropic work is no solution to the 
                                                            
29 Ibid,101. 
30 The Bill & Melinda Gates Foundation is the largest transparently operated private foundation in the world, 
founded by Bill and Melinda Gates. The primary aim of the foundation is to enhance healthcare and reduce extreme 
poverty. For further details visit <http://www.gatesfoundation.org/press-releases/Pages/comprehensive-hiv-aids-
partnership-000710.aspx>, (last accessed date April 25, 2012). 
31 Bristol-Myers Squibb Philanthropy, “An Introduction To Secure The Future”, last accessed date April 25, 
2012http://www.securethefuture.com/our_experience/commitment.shtml. 
32 Pfizer, “Global Health Infectious disease”, The world’s largest research based Pharmaceutical company, last 
accessed date April 25, 2012,doi:
 http://www.pfizer.com/responsibility/global_health/%20infectious_diseases_institute.jsp.  
33 Novartis Global, “Access to Health Care”,doi:http://www.novartis.com/corporate-responsibility/access-to-
healthcare/index.shtml, (last accessed date April 25, 2012). 
34 Abbot Laboratories, “Global Health Care & Medical Research”, last accessed date April 25, 
2012,doi:http://www.abbott.com/index.htm. 
35 Alec Van Gelder : Philip Stevens, “The Compulsory License Red Herring”, International Policy Network, 
(2010),last accessed date March 23,2012,9,
 http://scholar.googleusercontent.com/scholar?q=cache:7yHHlJFIXuwJ:scholar.google.com/+Roche+v.+Na
tco&hl=en&as_sdt=0,5. 
problem of access to essential medicines. Some substantial steps must be taken both at 
national and global level to overcome the barriers to access to necessary drugs.  
3. Rationale of Compulsory Licensing 
 
“Compulsory licensing36 is a license issued by a state authority to a government agency, a 
company or other party to use a patent without the patent holder’s consent”.37 The patent holder 
is, however, entitled to receive royalty for the use of their patent without their consent.
38
 
Patents, no doubt, play a vital role in promoting innovation and creativity. Without patent 
protection innovators will not have an incentive to make new innovations. Absence of patents, on 
the other hand, means absence of monopoly rights and low prices of products is an obvious 
result. But low prices at the cost of innovation are detrimental for the society in the long run 
because the society will be deprived of innovations and improved products.
39
 Despite their 
conflict with competition laws, patents have been accepted globally as a compromise to 
encourage innovation. Patents come into conflict with human rights law when monopolistic 
patent rights are conferred on the products which are essential for human life.
40
 
                                                            
36 The birth of the concept of compulsory licenses is linked to the obligation, introduced by the United Kingdom 
(UK) Statute of Monopolies in 1623. Compulsory licensing has been reported to be popular in Britain as early as 
1850s. Later it was recognized by the international community through Paris Convention of 1883. 
For details visit doi: http://www.legislation.gov.uk/aep/Ja1/21/3/contents, (last accessed date February 13, 2012). 
37 Ebenezer Durojaye, “Compulsory Licensing And Access To Medicines In Post Doha Era: What Hope For 
Africa?”, Journal of Intellectual Property Law,  Vol. 18 Issue 2,35, (Spring2011), last accessed date 
February 13, 2012, 
doi:http://web.ebscohost.com/ehost/results?sid=b06a26af-6028-4687-93e0-
06fa097c0197%40sessionmgr13&vid=19&hid=122&bquery=(compulsory+licensing)&bdata=JmRiPWE5aCZ0eXB
lPTAmc2l0ZT1laG9zdC1saXZl. 
38 Ibid, 35. 
39 Aidan Hollis, “The Link Between Publicly Funded Health Care And Compulsory Licensing”, CMAJ: Canadian 
Medical Association Journal, Vol. 167 Issue 7, (2002),756, last accessed date February 13, 2012 , 
doi:http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=28&hid=122&sid=b06a26af-6028-4687-93e0-
06fa097c0197%40sessionmgr13.  
40 Jakkrit Kuanpoth, “Give The Poor Patients A Chance: Enhancing Access To Essential Medicines Through 
Compulsory Licensing”, Journal of Generic Medicines, Vol. 6 Issue 1, (Nov2008), 1,last accessed date February 13, 
2012, 
Multi-national pharmaceutical companies own patents on drugs and set exorbitantly high 
prices for patented drugs to maximize their profits; this renders prices of life-saving medicines 
unaffordable for common masses in the third world where per capita income is very low as 
compared to advanced countries. In case of national emergency, the availability of needed drugs 
becomes even more uncertain. To deal with such situations, TRIPS provides flexibility to 
national governments to invoke compulsory licensing provisions. It is pertinent to note here that 
for issuance of compulsory license national emergency is not the only ground. Under Doha 
Declaration on Public Health 2001 WTO member states have been provided the freedom to 
determine grounds of compulsory licensing.
41
 The grounds for granting compulsory licensing 
vary from country to country because international norms and standards for this practice have not 
developed so far. 
Following Indian case is an example where compulsory licensing provisions have been 
invoked to deal with the issue of affordability of the patented drug. 
4. Bayer Corporation42 v. Natco Pharma Limited 
4.1 Sorafenib Tosylate 
Sorafenib, originally patented in the United States in 1999
43
, is a kidney and liver cancer 
patented drug of Bayer Corporation which is sold under the brand name ‘Nexavar’. Sorafenib is 
                                                                                                                                                                                               
doi:http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=27&hid=122&sid=b06a26af-6028-4687-93e0-
06fa097c0197%40sessionmgr13. 
41 Manthan Janodia,  Rao J. Venkata & Udupa, N., “Correspondence”, Current Science, Vol. 91 Issue 8, 
(2006),998,last accessed date February 13, 2012,  
doi:http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=28&hid=122&sid=b06a26af-6028-4687-93e0-
06fa097c0197%40sessionmgr13  
42 Bayer AG is chemical and pharmaceutical company founded in Germany in 1863. It is well known for its original 
brand of Aspirin. For over a quarter of a century, Aspirin became synonymous with Bayer but the company lost its 
naming right during World War 1, due to its German origin. Bayer started its marketing in America soon after its 
inception in Germany. Bayer Corporation, a party in the case Bayer v. Natco, is American arm of Bayer. Bayer 
Corporation is an internationally renowned manufacturer of innovative drugs. In the 1990s, it invented ‘sorafenib’, a 
liver and kidney cancer drug which is subject of controversy in the Bayer v. Natco case. 
For details visit <http://en.wikipedia.org/wiki/Bayer_USA>, (last accessed date June 8, 2012). 
not a life-saving drug, but a life extending or life prolonging drug.
44
  The life of a patient can be 
extended by 4-5 years and 6-8 months in the case of kidney cancer and liver cancer respectively. 
It is pertinent to mention that the patient needs to use the pharmaceutical throughout their 
lifetime.
45
 It is also worthy noting that in India, one month dose of Sorafenib costs Rs.2,80,428/- 
(Rs.33,65,136/- per annum).
46
 
On January 12, 2001, Bayer applied for Sorafenib product patent in India. The patent was 
granted on March 3, 2008 under patent number 215758.
47
 The drug was, however, launched in 
India in 2009 after receiving regulatory approval for importation.
48
 
4.2 The Compulsory Licensing Application by Natco 
Natco Pharma Ltd. developed the process for manufacturing of Sorafenib and in April 
2011, received a license from the Drug Controller General of India for bulk manufacturing and 
marketing of Sorafenib in India. Natco Pharma approached Bayer Corporation for a voluntary 
license to manufacture and sell a generic version of their patented pharmaceutical product in 
India. The voluntary license was, however, denied by the Bayer Corporation. 
                                                                                                                                                                                               
43 Raja Murthy, “India patent bypass delivers life-saving blow against cancer”, last accessed date April 20, 2012, 
doi:http://www.atimes.com/atimes/South_Asia/NC21Df01.html. 
44 Betsy Vinolia Rajasingh, “India's first compulsory licence over Bayer's patent”, (2012), .last accessed date April 
20,2012, doi:http://jiplp.blogspot.com/2012/05/indias-first-compulsory-licence-over.html 
45 Frederick Noble , “Indian Patent Office Grants License For Anti-Cancer Drug”, 
doi:http://www.albrightpatents.co.uk/articles/indian-patent-office-grants-licence-for-anti-cancer-drug/, (last accessed 
date April 20,2012). 
46 NATCO Pharma Limited v. Bayer corporation, CLA, no 1, 2011. Available online at 
<http://ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf>, (last accessed date June 8, 2012). 
47 Joseph Alexander, “Planning Commission Calls For Grant Of More Compulsory Licences To Ensure Drug 
Security”, Pharmabiz, doi:http://pharmabiz.com/NewsDetails.aspx?aid=68849&sid=1, (last accessed date April 
20,2012). 
48 Patricia Van Arnum, “Pharmaceutical Industry Faces Compulsory Licensing in India”, Pharamatech, 2012, 
<http://www.pharmtech.com/pharmtech/Pharmaceutical-Industry-Faces-Compulsory-
Licensing/ArticleStandard/Article/detail/766949?ref=25>, (last accessed date April 20,2012). 
Under Indian patent law, an application for compulsory licensing is allowed only after a 
lapse of three years after the grant of patent. Since the patent was granted in 2008, on July 29, 
2011, Natco filed an application before the Controller General of Patents, Designs and 
Trademarks (CGPDTM) for the compulsory license in respect of Sorafenib under Section 
84(1)(a)(b)(c) of the Indian Patent Act 1970.
49
 Natco alleged that the patented invention does not 
satisfy the reasonable requirements of the public; the patented invention is not available to the 
public at a reasonably affordable price; and the patented invention is not worked in the territory 
of India. Moreover, Natco Pharma proposed to sell the drug at a price of Rs.8800 for a month’s 
therapy.
50
 
4.3 Preliminary Issues Raised by the Patentee 
 On October 7, 2011, Bayer Corporation filed an interlocutory petition seeking a stay on 
the ground that Natco Pharma had infringed their patent on Sorafenib and an infringement suit 
against Natco was pending in the Delhi High Court. On October 27, 2011, the Patent Office 
refused the patentee’s request for a stay in the matter. The parties were heard on January 13, 
2012 and the patentee raised several preliminary issues during the course of the hearing. For 
instance, the patentee raised an issue that the application should be rejected on the ground that 
the applicant had suppressed a material fact that Cipla, another generic manufacturer in India, 
had been selling Sorafenib at the cost of Rs.30,000/- for a month’s therapy since April 2010. 
Natco Pharma in reply submitted that they were aware of the pending infringement suit 
filed by the patentee against Cipla but it was not suppression of a material fact because the 
                                                            
49 Patralekha Chatterjee, “India’s Generics-Big Pharma Battle Drops Drug Prices, Raises Legal Debate”, 
doi:http://www.ip-watch.org/2012/05/20/india%E2%80%99s-generics-big-pharma-battle-drops-drug-prices-raises-
legal-debate/, (last accessed date April 20,2012) 
50  Arnum, “Pharmaceutical Industry Faces Compulsory Licensing in India” 2012.  
pending suit had no relevance to the compulsory licensing application. It was the duty of the 
patentee and not of any third party to meet the demand of the patented drug in the Indian market. 
Moreover, an infringement suit was pending against Cipla. Cipla could be injuncted by the High 
Court at anytime and supply of Sorafenib by Cipla could stop totally. The objection raised by the 
patentee was therefore overruled. 
4.4 The Main Issue/Controversy 
 As the application for the grant of compulsory license was made under Section 
84(1)(a)(b)(c) of the Indian Patent Act 1970, the main issues to be decided in the case were as 
under: 
- Whether the reasonable requirements of the public with respect to the patented invention 
had not been satisfied. 
- Whether the patented invention was not avail able to the public at a reasonably affordable 
price. 
- Whether the patented invention was not worked in the territory of India.51 
Under Indian patent laws, compulsory license could be granted if anyone of these three 
grounds was established.
52
 The submissions of the Applicant and the Patentee on these issues are 
as under: 
- Reasonable Requirements of the Public 
                                                            
51 “Compulsory licensing: Road ahead” , doi;http://viamediagroup.in/paradox.html>,  (last accessed date June 4, 
2012) 
52 Khomba Singh, “Bayer demands withdrawal of Natco Pharma's compulsory licence”, 
doi:http://articles.economictimes.indiatimes.com/2012-05-19/news/31778153_1_compulsory-licence-natco-pharma-
compulsory-licensing, (last accessed date June 4, 2012). 
The Applicant relied on statistics published in GLOBOCAN 2008
53
 to support their contention 
that Bayer’s patented invention had failed to fulfill the reasonable requirements of the public. 
According to the publication, there were approximately 20000 liver cancer patients in India 
while the number of kidney cancer patients was about 8900. Whereas no bottles of Sorafenib 
were imported in 2008 and only 200 bottles of the patented drug were imported in 2009. There 
was a huge difference between supply and demand of the drug. Consequently, the product in 
question was out of stock or not available in common pharmacies even in metro cities of India. 
The patentee thus failed to meet the demand of even 1% patients in India, the Applicant 
contended. 
In reply, the patentee also relied on GLOBOCAN 2008 contending that Sorafenib was 
needed by the liver and kidney cancer patients who were in advanced stage.
54
 Thus 
approximately 4838 (out of 20000) liver cancer patients and about 4004 (out of 8900) kidney 
cancer patients were entitled for treatment with Sorafenib. Moreover, the patentee argued that 
supply of the drug was not necessary in villages as the treatment with the drug should be 
supervised by doctors.
55
 Furthermore, the patentee argued that supply of the drug was 
considerably enhanced due to sale of Sorafenib by Cipla.
56
 
- Reasonably Affordable Price 
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56, Krishna & Saurastri “Natco win: Deterrent for FDI?”. 
 The Applicant contended that price of the drug was too high for a common man in India 
and the patentee had failed to meet the demand for the drug on reasonable terms. Rs.2,80,428 –
price fixed by Bayer Corporation for a month’s therapy- was more than total income of three and 
half years of a government worker in India.
57
 About 30% Indians were already below the poverty 
line
58
; the exorbitant price of the drug would push more Indian population below the poverty 
line.
59
 Setting of such a high cost of the drug was unfair, anti-competitive and misuse of the 
monopolistic rights, contended the Applicant. 
The patentee, in reply, justified the high price on the ground that innovation was not 
possible without huge costs spent on research and development. Manufacturing of innovative 
products was different from that of generics which are mere copies of the patented products. 
Almost 75% of the total research and development cost was incurred on failed projects. That cost 
too was recouped by setting a high price of successful formulas. Moreover, the patentee 
submitted that the term ‘reasonable’ means reasonable not only to public but also to patentee. 
Therefore there must be a balance between public interest and interest of the innovator taking 
into account the cost incurred on research and development.
60
 
- Patented Invention not Worked in the Territory of India 
 The Applicant contended that the patented invention was not worked in the territory of 
India because it was being imported into India and not being manufactured in India. The patentee 
had failed to exploit the patent in India without ascribing any reason for such neglect. The 
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patentee already having manufacturing facilities in India had no excuse for not working the 
patent in India.
61
 
In reply, the patentee argued that ‘worked in India’ did not mean ‘manufactured in India’. 
Domestically worked meant ‘commercial working’ or ‘supplied to the Indian markets’.62 Bayer 
argued that the words ‘manufacture in India’ were deleted from Section 84(7)(a)(ii) while 
amending the patent law in 2002.
63
 Moreover, the patentee contended that manufacturing of the 
product required huge investments on infrastructure and logistics which could further increase 
the manufacturing cost of Sorafenib -a product of small global demand. The quantity of the 
product required in India therefore did not justify spending of huge amounts on infrastructure 
and logistics.
64
 Furthermore, under Article 27 of the TRIPS Agreement, the patentee’s right 
should not be affected only because of importation of the patented product.
65
 
4.5 The Order of Grant of Compulsory License 
 After 18 hours of hearings in three days, on March 9, 2012, minutes before leaving his 
office on the last day of his stint at the Indian Patent Office, P.H Kurian, Controller General of 
Patents, issued the order of grant of first Indian compulsory license
66
 to Natco Pharma allowing 
it to manufacture and sell Bayer’s patented product Sorafenib.67 
                                                            
61 Jose Madan, Adheesh Nargolkar and Fiona Desouza of Khaitan & Co, A Rare Win for Natco!, 
<http://www.moneycontrol.com/news/features/a-rare-win-for-natco_682506.html>, (last accessed date June 4, 
2012) 
62 Krishna & Saurastri  “Natco win: Deterrent for FDI?”,2012 
63 Rajasingh, “India's first compulsory licence over Bayer's patent”, 2012, 
64 NATCO Pharma Limited v. Bayer corporation, CLA, no 1, 2011, Available online at 
<http://ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf>, (last accessed date June 8, 2012). 
65 Krishna & Saurastri , “Natco win: Deterrent for FDI?”,(2012) 
66 The compulsory licence is valid till the patent for Nexavar expires in 2021. 
<http://www.business-standard.com/india/news/us-to-keep-an-eyeindias-compulsory-drug-licensing-
move/473520/>, (last accessed date June 9, 2012). 
67 Breaking News: “India's First Compulsory License Granted”, (2012), 
doi:http://ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf>, (last accessed date June 4, 2012) 
As regards the question of meeting reasonable requirements of the public, the Controller 
concluded that even if Bayer’s estimate of cancer patients in India is accepted, the negligible 
quantity of the drug imported into India by Bayer could hardly suffice for 2 percent cancer 
patients.
68
 This nominal quantity of the drug was available only at certain premier hospitals and 
that too was excessively high-priced rendering it unaffordable for potential users. The Controller 
therefore concluded that the patentee had not adequately met the demand of the patented 
invention on reasonable terms.
69
 
As regards the question of reasonably affordable price, the Controller rejected Bayer’s 
interpretation of the term and concluded that the term ‘reasonable’ used in the provision referred 
predominantly to the purchasing power of the public.
70
 
With regards to question of ‘working of the patented invention in the territory of India’, 
the Controller referred to Article 5(A)(2) of the Paris Convention according to which patentee’s 
failure to work the invention may be used as a ground for grant of compulsory license. 
Moreover, the Controller referred to Article 2(1) of the TRIPS Agreement under which member 
countries are required to comply with provisions of the Paris Convention. Furthermore, the 
Controller referred to Section 83(b) of the Patents Act 1970 (India) which stipulates that: “they 
(patents) are not granted merely to enable patentees to enjoy a monopoly for the importation of 
the patented article.”71 Applying the rationale of Section 83(b), the Controller concluded that 
working of the invention in India meant manufacturing of the patented product in India and not 
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mere its importation in India. Bayer had therefore failed to comply with Section 84(1)(c) of the 
Indian Patent Act 1970.
72
 
The grant of compulsory license was, however, subject to certain conditions. Firstly, 
Natco was required to pay a 6% royalty to Bayer on net sales of Sorafenib manufactured under 
the compulsory license. Secondly, Natco was not allowed to charge more than Rs.8800 for a 
month’s therapy.73 Thirdly, Natco was required to manufacture the drug at its own 
manufacturing facility. Fourthly, the generic version of the drug could only be sold within 
territory of India and Natco was not allowed to export the drug.
74
 Fifthly, the generic version 
must have a distinct physical appearance, trade name, and packaging.
75
 Moreover, Natco Pharma 
committed to donate the drug free of cost to six hundred needy patients every year. The 
Controller also recorded this commitment in the order for the grant of compulsory license.
76
 
The Controller’s decision, which brought down the costs Sorafenib by 97 percent, was 
appreciated by many, especially cancer patients, human rights activists and advocates of cheaper 
drugs, who believe that it would bring relief, hope and cheer for helpless cancer patients
77
 in 
India who –in the absence of any form of health insurance- were unable to afford the excessively 
expensive therapy otherwise.
78
 The price set by the patentee could be afforded only by richest 
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patients in India and importation of a very negligible quantity of the drug was testimony to this 
fact.
79
 
Supporters of the ruling believed that this bold decision would check abuse of patent 
rights and put pressure on other brand name pharmaceutical companies to rethink and revise 
prices of their products. Soon after this judgment, Roche Holding, a Swiss drug maker, 
announced that it will cut price on two of its cancer drugs, Herceptin and Mabthera
80
, and 
partnered with an Indian pharmaceutical company Emcure Pharmaceuticals to repackage and sell 
the same under different brand names only in the Indian markets.
81
 
5. Conclusion 
Patents cause overpricing of patented products as a result of monopoly rights provided to 
patent owner for a period of twenty years. Despite this fact patents have been accepted globally 
as a necessary evil because patents provide incentive to innovators to further innovate. In case of 
pharmaceutical patents, monopoly rights enjoyed by patent owners have serious human rights 
implications because the price set by the patent owner to maximize their profits may be 
unaffordable for patients especially in the third world countries where purchasing power of 
general masses is low. 
Compulsory licensing has been provided under TRIPS Agreement as a safeguard to make 
sure that monopoly rights are not abused by patent owners especially in cases of public health 
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crisis. Compulsory licensing is condemned by advanced countries and multi-national companies 
because use of compulsory licensing reduces their profits. Compulsory licensing is a violation of 
the rights of the patent holder. But in certain cases where human lives are at risk owing to 
unaffordability of needed drugs, it may not be possible to fully protect corporate interests of 
multi-national companies.   
 
 
 
 
